HOWL · Werewolf Therapeutics Inc
United States · RS rating 94 · As of 2026-11-03
| Price | 1.07 USD |
|---|---|
| 1-day change | +1.9% |
| RS rating (overall / 1M / 3M / 12M) | 94 / 89 / 97 / 38 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 44 / 72 / 66 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +44.4% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +18.3% |
| Market cap (USD) | $41.8M |